Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study-Reference-Cited by-同舟云学术

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

Published:2022-01 Issue:1 Volume:23 Page:65-76
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Usmani Saad Z,Quach Hang,Mateos Maria-Victoria,Landgren Ola,Leleu Xavier,Siegel David,Weisel Katja,Gavriatopoulou Maria,Oriol Albert,Rabin Neil,Nooka Ajay,Qi Ming,Beksac Meral,Jakubowiak Andrzej,Ding Bifeng,Zahlten-Kumeli Anita,Yusuf Akeem,Dimopoulos Meletios

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Multiple myeloma: diagnosis and treatment;Michels;Am Fam Physician,2017

2. Relapsed refractory multiple myeloma: a comprehensive overview;Bazarbachi;Leukemia,2019

3. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

4. Management of multiple myeloma in the relapsed/refractory patient;Sonneveld;Hematology (Am Soc Hematol Educ Program),2017

5. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience;Holstein;Drugs,2017

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

2. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil;Cancers;2024-09-03

3. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting;Journal of Comparative Effectiveness Research;2024-09

4. Treatment of Early Relapse: Non-CAR T Cells;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies;Hematological Oncology;2024-08-03